| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
Eikon Therapeutics, Inc.
13D
SRZN · 86889P208
|
11.6% |
2/12/2026
Event 2/6/2026
|
||||
| The Column Group IV GP, LP | 8.3% | |||||
| The Column Group IV, LP | 8.0% | |||||
| The Column Group IV-A, LP | 0.3% | |||||
| The Column Group Opportunity III, LP | 3.5% | |||||
| The Column Group Opportunity III GP, LP | 3.5% | |||||
| TCG Opportunity III GP, LLC | 3.5% | |||||
| Tim Kutzkey | 11.6% | |||||
| Peter Svennilson | 11.6% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.